Virtus Biotech Clinical Trials ETF BBC

Morningstar Medalist Rating

Morningstar’s Analysis BBC

Will BBC outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Virtus LifeSci Biotech Clinical Trls ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings BBC

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings17.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Kodiak Sciences Inc

2.48761,716
Healthcare

Xencor Inc

2.35720,146
Healthcare

First Tracks Biotherapeutics Inc

2.06630,221
Healthcare

Replimune Group Inc

1.87573,320
Healthcare

AbCellera Biologics Inc Ordinary Shares

1.61493,676
Healthcare

Viridian Therapeutics Inc

1.60489,217
Healthcare

Amylyx Pharmaceuticals Inc

1.55476,114
Healthcare

SELLAS Life Sciences Group Inc

1.52465,765
Healthcare

SpyGlass Pharma Inc

1.44440,566
Healthcare

MBX Biosciences Inc

1.21372,566
Healthcare

Sponsor Center